Atypisches hämolytisch-urämisches Syndrom: Differentialdiagnostik und Therapie

Das atypische hämolytisch-urämische Syndrom ist eine wichtige Differenzialdiagnose bei thrombotischer Mikroangiopathie [1]. Da eindeutige Biomarker fehlen, handelt es sich um eine Diagnose im Ausschlussverfahren. Wenn eine adäquate Therapie ausbleibt oder verzögert erfolgt, ist die Prognose ungünstig. Umso wichtiger sind zeitnahe differenzialdiagnostische Abwägungen und Therapieeinleitung. Dieser Leitfaden soll hierbei eine Hilfestellung geben.

Abstract

Atypical hemolytic uremic syndrome (aHUS) is an important differential diagnosis in thrombotic microangiopathy (TMA). The absence of definitive biomarkers usually allows for aHUS to be diagnosed only through a process of exclusion. Due to the unfavorable prognosis if adequate therapy is delayed or not provided, differential diagnostic considerations and initiation of treatment must occur promptly. The presented guideline is intended to serve as an aid in this process.

Schlüsselwörter

thrombotische Mikroangiopathie - atypisches hämolytisch-urämisches Syndrom - Differentialdiagonse - Therapie

Keywords

thrombotic microangiopathy - atypical hemolytic uremic syndrome - differential diagnosis - therapy

Publication History

Article published online:
29 January 2025

• Literatur

• 1 Schönermarck U, Ries W, Schröppel B. et al. Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J 2019; 13 (02) 208-216
• 2 Yan K, Desai K, Gullapalli L. et al. Epidemiology of atypical hemolytic uremic syndrome: a systemic literature review. Clin Epidemiol 2020; 12: 295-305
• 3 Fakhouri F, Zuber J, Frémeaux-Bacchi V. et al. Haemolytic uraemic syndrome. Lancet 2017; 390: 681-696
• 4 Li A, Makar R, Hurwitz S. et al. Treatment with or without plasma exchange for patients with acquired thrombotic microangiopathy not associated with severe ADAMTS13 deficiency: a propensity score-matched study. Transfusion 2016; 56 (08) 2069-2077
• 5 Fremeaux-Bacchi V, Fakhouri F, Garnier A. et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8 (04) 554-562
• 6 Walle J, Delmas Y, Ardissino G. et al. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 2017; 30 (01) 127-134
• 7 Jokiranta T, Viklicky O, Al Shorafa S. et al. Differential diagnosis of thrombotic microangiopathy in nephrology. BMC Nephrol 2017; 18 (01) 324
• 8 Bommer M, Wölfle-Guter M. et al. Differenzialdiagnose und Therapie thrombotischer Mikroangiopathien. Dtsch Arztebl Int 2018; 115 (19) 327-334
• 9 AWMF: S2k-Leitlinie Hämolytisch-Urämisches Syndrom im Kindesalter (Uptdate 2022). Accessed August 23, 2024 at: https://register.awmf.org/de/leitlinien/detail/166–002
• 10 Bendapudi P, Hurwitz S, Fry A. et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol 2017; 4 (04) e157-e164
• 11 Coppo P, Schwarzinger M, Buffet M. et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 2010; 5 (04) e10208
• 12 Fage N, Orvain C, Henry N. et al. Proteinuria increases the PLASMIC and French Scores performance to predict thrombotic thrombocytopenic purpura in patients with thrombotic microangiopathy syndrome. Kidney Int Rep 2021; 7 (02) 221-231
• 13 Legendre C, Licht C, Muus P. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368 (23) 2169-2181
• 14 Greenbaum L, Fila M, Ardissino G. et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016; 89 (03) 701-711
• 15 Rondeau E, Scully M, Ariceta G. et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int 2020; 97 (06) 1287-1296
• 16 Tanaka K, Adams B, Aris A. et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol 2021; 36 (04) 889-898
• 17 Haas C, Nitschke M, Menne J. et al. Charakterisierung von Patienten mit atypischem hämolytisch-urämischen Syndrom (aHUS) in Deutschland, Daten aus dem globalen aHUS-Register. Nephrologe 2019; 14: 496-504